实体肿瘤免疫治疗的关键问题与对策
发布时间：2018-11-07 20:28
【摘要】：近年来,肿瘤免疫治疗取得重大突破性进展,以CAR-T为代表的细胞免疫治疗在血液肿瘤的治疗中取得了令人鼓舞的临床疗效,免疫卡控点抑制剂CTLA-4和PD-1/PD-L1单抗也相继获批用于临床。然而,大多数实体肿瘤患者并不能从免疫治疗中获益。本文从个体化新抗原表位的筛选、免疫细胞活力的维持、免疫细胞趋化与浸润、临床治疗模式和评价标准等方面总结了实体肿瘤免疫治疗难以见效的关键问题,并且从临床应用角度阐述其应对策略。
[Abstract]:In recent years, great breakthrough has been made in tumor immunotherapy. Cellular immunotherapy, represented by CAR-T, has achieved encouraging clinical results in the treatment of blood tumors. CTLA-4 and PD-1/PD-L1 McAbs were also approved for clinical use. However, most patients with solid tumors do not benefit from immunotherapy. In this paper, the key problems of solid tumor immunotherapy are summarized from the following aspects: screening of individual new antigen epitopes, maintenance of immune cell viability, chemotaxis and infiltration of immune cells, clinical treatment model and evaluation criteria, etc. And from the clinical application point of view to explain its coping strategy.
【作者单位】： 南京大学医学院附属鼓楼医院肿瘤中心暨临床肿瘤研究所;
【基金】：国家自然科学基金资助项目(No.81672367)~~
【分类号】：R730.51
[Abstract]:In recent years, great breakthrough has been made in tumor immunotherapy. Cellular immunotherapy, represented by CAR-T, has achieved encouraging clinical results in the treatment of blood tumors. CTLA-4 and PD-1/PD-L1 McAbs were also approved for clinical use. However, most patients with solid tumors do not benefit from immunotherapy. In this paper, the key problems of solid tumor immunotherapy are summarized from the following aspects: screening of individual new antigen epitopes, maintenance of immune cell viability, chemotaxis and infiltration of immune cells, clinical treatment model and evaluation criteria, etc. And from the clinical application point of view to explain its coping strategy.
【作者单位】： 南京大学医学院附属鼓楼医院肿瘤中心暨临床肿瘤研究所;
【基金】：国家自然科学基金资助项目(No.81672367)~~
【分类号】：R730.51
【相似文献】
相关期刊论文 前10条
1 ;“肿瘤免疫治疗的成功与挑战”国际研讨会成功召开[J];中国医药生物技术;2011年05期
2 魏素菊;王俊艳;洪雷;;基于细胞的肿瘤免疫治疗研究进展[J];药品评价;2012年18期
3 杨爱珍;项方;贾绍昌;;肿瘤免疫治疗疗效评估方法的进展[J];江苏医药;2012年17期
4 胡锦跃;孙去病;;肿瘤免疫治疗中的科学思维[J];医学与哲学;1993年07期
5 阮连贵;;全国肿瘤免疫治疗学术会简报[J];沈阳部队医药;1996年01期
6 杨举伦,帛岚湘,陈华;肿瘤浸润淋巴细胞与肿瘤免疫治疗[J];西南国防医药;1997年03期
7 张丹;肿瘤免疫治疗研究进展[J];临床耳鼻咽喉科杂志;2003年03期
8 肖兰凤,朱永湘,邱p，
本文编号：2317486
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2317486.html
